Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Lundgren, JR, Janus, C, Jensen, SBK, Juhl, CR, Olsen, LM, Christensen, RM, Svane, MS, Bandholm, T, Bojsen-Møller, KN, Blond, MB, Jensen, J-EB, Stallknecht, BM, Holst, JJ, Madsbad, S & Torekov, SS 2021, 'Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined', The New England journal of medicine, bind 384, nr. 18, s. 1719-1730. https://doi.org/10.1056/NEJMoa2028198

APA

Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., Jensen, J-E. B., Stallknecht, B. M., Holst, J. J., Madsbad, S., & Torekov, S. S. (2021). Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. The New England journal of medicine, 384(18), 1719-1730. https://doi.org/10.1056/NEJMoa2028198

CBE

MLA

Vancouver

Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM o.a. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. The New England journal of medicine. 2021 maj 6;384(18):1719-1730. https://doi.org/10.1056/NEJMoa2028198

Author

Lundgren, Julie R ; Janus, Charlotte ; Jensen, Simon B K ; Juhl, Christian R ; Olsen, Lisa M ; Christensen, Rasmus M ; Svane, Maria S ; Bandholm, Thomas ; Bojsen-Møller, Kirstine N ; Blond, Martin B ; Jensen, Jens-Erik B ; Stallknecht, Bente M ; Holst, Jens J ; Madsbad, Sten ; Torekov, Signe S. / Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. I: The New England journal of medicine. 2021 ; Bind 384, Nr. 18. s. 1719-1730.

Bibtex

@article{798110c0e07d44a8b57f0af0e97ed118,
title = "Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined",
abstract = "BACKGROUND Weight regain after weight loss is a major problem in the treatment of persons with obesity. METHODS In a randomized, head-to-head, placebo-controlled trial, we enrolled adults with obesity (body-mass index [the weight in kilograms divided by the square of the height in meters], 32 to 43) who did not have diabetes. After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous–intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus liraglutide therapy (combination group); or placebo plus usual activity (placebo group). End points with prespecified hypotheses were the change in body weight (primary end point) and the change in body-fat percentage (secondary end point) from randomization to the end of the treatment period in the intention-to-treat population. Prespecified metabolic health-related end points and safety were also assessed. RESULTS After the 8-week low-calorie diet, 195 participants had a mean decrease in body weight of 13.1 kg. At 1 year, all the active-treatment strategies led to greater weight loss than placebo: difference in the exercise group, −4.1 kg (95% confidence interval [CI], −7.8 to −0.4; P=0.03); in the liraglutide group, −6.8 kg (95% CI, −10.4 to −3.1; P<0.001); and in the combination group, −9.5 kg (95% CI, −13.1 to −5.9; P<0.001). The combination strategy led to greater weight loss than exercise (difference, −5.4 kg; 95% CI, −9.0 to −1.7; P=0.004) but not liraglutide (−2.7 kg; 95% CI, −6.3 to 0.8; P=0.13). The combination strategy decreased body-fat percentage by 3.9 percentage points, which was approximately twice the decrease in the exercise group (−1.7 percentage points; 95% CI, −3.2 to −0.2; P=0.02) and the liraglutide group (−1.9 percentage points; 95% CI, −3.3 to −0.5; P=0.009). Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness. Increased heart rate and cholelithiasis were observed more often in the liraglutide group than in the combination group. CONCLUSIONS A strategy combining exercise and liraglutide therapy improved healthy weight loss maintenance more than either treatment alone.",
author = "Lundgren, {Julie R} and Charlotte Janus and Jensen, {Simon B K} and Juhl, {Christian R} and Olsen, {Lisa M} and Christensen, {Rasmus M} and Svane, {Maria S} and Thomas Bandholm and Bojsen-M{\o}ller, {Kirstine N} and Blond, {Martin B} and Jensen, {Jens-Erik B} and Stallknecht, {Bente M} and Holst, {Jens J} and Sten Madsbad and Torekov, {Signe S}",
note = "Copyright {\textcopyright} 2021 Massachusetts Medical Society.",
year = "2021",
month = may,
day = "6",
doi = "10.1056/NEJMoa2028198",
language = "English",
volume = "384",
pages = "1719--1730",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachusetts Medical Society",
number = "18",

}

RIS

TY - JOUR

T1 - Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

AU - Lundgren, Julie R

AU - Janus, Charlotte

AU - Jensen, Simon B K

AU - Juhl, Christian R

AU - Olsen, Lisa M

AU - Christensen, Rasmus M

AU - Svane, Maria S

AU - Bandholm, Thomas

AU - Bojsen-Møller, Kirstine N

AU - Blond, Martin B

AU - Jensen, Jens-Erik B

AU - Stallknecht, Bente M

AU - Holst, Jens J

AU - Madsbad, Sten

AU - Torekov, Signe S

N1 - Copyright © 2021 Massachusetts Medical Society.

PY - 2021/5/6

Y1 - 2021/5/6

N2 - BACKGROUND Weight regain after weight loss is a major problem in the treatment of persons with obesity. METHODS In a randomized, head-to-head, placebo-controlled trial, we enrolled adults with obesity (body-mass index [the weight in kilograms divided by the square of the height in meters], 32 to 43) who did not have diabetes. After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous–intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus liraglutide therapy (combination group); or placebo plus usual activity (placebo group). End points with prespecified hypotheses were the change in body weight (primary end point) and the change in body-fat percentage (secondary end point) from randomization to the end of the treatment period in the intention-to-treat population. Prespecified metabolic health-related end points and safety were also assessed. RESULTS After the 8-week low-calorie diet, 195 participants had a mean decrease in body weight of 13.1 kg. At 1 year, all the active-treatment strategies led to greater weight loss than placebo: difference in the exercise group, −4.1 kg (95% confidence interval [CI], −7.8 to −0.4; P=0.03); in the liraglutide group, −6.8 kg (95% CI, −10.4 to −3.1; P<0.001); and in the combination group, −9.5 kg (95% CI, −13.1 to −5.9; P<0.001). The combination strategy led to greater weight loss than exercise (difference, −5.4 kg; 95% CI, −9.0 to −1.7; P=0.004) but not liraglutide (−2.7 kg; 95% CI, −6.3 to 0.8; P=0.13). The combination strategy decreased body-fat percentage by 3.9 percentage points, which was approximately twice the decrease in the exercise group (−1.7 percentage points; 95% CI, −3.2 to −0.2; P=0.02) and the liraglutide group (−1.9 percentage points; 95% CI, −3.3 to −0.5; P=0.009). Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness. Increased heart rate and cholelithiasis were observed more often in the liraglutide group than in the combination group. CONCLUSIONS A strategy combining exercise and liraglutide therapy improved healthy weight loss maintenance more than either treatment alone.

AB - BACKGROUND Weight regain after weight loss is a major problem in the treatment of persons with obesity. METHODS In a randomized, head-to-head, placebo-controlled trial, we enrolled adults with obesity (body-mass index [the weight in kilograms divided by the square of the height in meters], 32 to 43) who did not have diabetes. After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous–intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus liraglutide therapy (combination group); or placebo plus usual activity (placebo group). End points with prespecified hypotheses were the change in body weight (primary end point) and the change in body-fat percentage (secondary end point) from randomization to the end of the treatment period in the intention-to-treat population. Prespecified metabolic health-related end points and safety were also assessed. RESULTS After the 8-week low-calorie diet, 195 participants had a mean decrease in body weight of 13.1 kg. At 1 year, all the active-treatment strategies led to greater weight loss than placebo: difference in the exercise group, −4.1 kg (95% confidence interval [CI], −7.8 to −0.4; P=0.03); in the liraglutide group, −6.8 kg (95% CI, −10.4 to −3.1; P<0.001); and in the combination group, −9.5 kg (95% CI, −13.1 to −5.9; P<0.001). The combination strategy led to greater weight loss than exercise (difference, −5.4 kg; 95% CI, −9.0 to −1.7; P=0.004) but not liraglutide (−2.7 kg; 95% CI, −6.3 to 0.8; P=0.13). The combination strategy decreased body-fat percentage by 3.9 percentage points, which was approximately twice the decrease in the exercise group (−1.7 percentage points; 95% CI, −3.2 to −0.2; P=0.02) and the liraglutide group (−1.9 percentage points; 95% CI, −3.3 to −0.5; P=0.009). Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness. Increased heart rate and cholelithiasis were observed more often in the liraglutide group than in the combination group. CONCLUSIONS A strategy combining exercise and liraglutide therapy improved healthy weight loss maintenance more than either treatment alone.

UR - http://www.scopus.com/inward/record.url?scp=85105435475&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa2028198

DO - 10.1056/NEJMoa2028198

M3 - Journal article

C2 - 33951361

VL - 384

SP - 1719

EP - 1730

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 18

ER -

ID: 65429930